Breaking News

LSU Baseball – Live on the LSU Sports Radio Network The US House advanced a package of 95 billion Ukraine and Israel to vote on Saturday Will Israel’s Attack Deter Iran? The United States agrees to withdraw American troops from Niger Olympic organizers unveiled a strategy for using artificial intelligence in sports St. John’s Student athletes share sports day with students with special needs 2024 NHL Playoffs bracket: Stanley Cup Playoffs schedule, standings, games, TV channels, time The Stick-Wielding Beast of College Sports Awakens: Johns Hopkins Lacrosse Is Back Joe Pellegrino, a popular television sports presenter, has died at the age of 89 The highest-earning athletes in seven professional sports

, /PRNewswire/ — Hemcheck Sweden AB has received an order from the AREVA research program in the USA. The order is a first order, has less economic value and is intended for research use. AREVA is a research program of the Geneva Foundation, a non-profit organization focused on research, development and education in military medicine. AREVA works with private organizations, academic institutions and government agencies and organizations such as the US military and the FDA.

– It is very exciting that we received this order. The American market is very large and AREVA has a large network of interesting organizations. Even if we do not have FDA approval, we believe that this collaboration can lead to more commercial opportunities in the future, says Joen Averstad, CEO of Hemcheck.

For additional information, please contact:

Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: [email protected]

Hemcheck Sweden AB, founded in 2010, manufactures and commercializes a patented, CE-marked concept for the detection of hemolysis at the point of care. The concept consists of single-use tests as well as readers that can very quickly, immediately after sampling, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, the rupture of red blood cells, is the most common global reason why blood samples cannot be analyzed accurately, and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolyzed blood samples in direct connection with near-patient blood sampling. In this way, Hemcheck can contribute to greater patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, [email protected], is the authorized advisor of the company.

This information is brought to you by Cision http://news.cision.com

https://news.cision.com/hemcheck/r/hemcheck-receives-order-from-research-program-in-the-united-states,c3640896

The following files are available for download:

Leave a Reply

Your email address will not be published. Required fields are marked *